Treatment of specific macrovascular beds in patients with diabetes mellitus by Petznick, Allison M & Shubrook, Jay H
REVIEW Open Access
Treatment of specific macrovascular beds in
patients with diabetes mellitus
Allison M Petznick
*, Jay H Shubrook
Abstract
In 2007, over 23 million people had diabetes in the United States and death from cardiovascular disease is esti-
mated to occur in 80% of those Americans. Risk factor reduction is the most important therapy for primary and
secondary prevention of macrovascular disease in patients with and without diabetes mellitus. Despite this, presen-
tation and response to therapy is often different for patients with diabetes compared to their non-diabetic coun-
terparts. This paper will review the current targets for therapy of cardiovascular disease, peripheral vascular disease,
and cerebrovascular disease in patients with diabetes.
In 2007, 23.6 million people in the United States had
diabetes [1]. Currently, death from cardiovascular dis-
ease (CVD) is estimated to occur in 80% or 18.4 million
of those Americans [1]. Many patients haven’te v e n
been diagnosed with type 2 diabetes until a cardiovascu-
lar event has already occurred. Approximately 30% of
patients with an acute MI are newly diagnosed with
type 2 diabetes prior to hospital discharge [2]. Diabetes
already costs the US population 174 billion dollars a
year in direct and indirect expenses [1]. It has been esti-
mated that 1 in 5 US Medicare dollars are spent on the
person with diabetes [3]. Diabetes, its projected expan-
sion, and its complications could cripple the economy of
our health care system. Unfortunately, we are currently
only observing the tip of the iceburg.
This paper will review the current targets for therapy
in risk factor reduction as well as the approach to
screening and therapy of cardiovascular disease, periph-
eral vascular disease, and cerebrovascular disease in
patients with diabetes.
Current Risk Factor Reduction Targets
Risk factor reduction is the most important therapy for
primary and secondary prevention of macrovascular dis-
ease in patients with diabetes. The greater the number
of risk factors, the greater the overall risk of macrovas-
cular disease [4]. Risk factor reduction includes lifestyle
management, blood pressure control, lipid management,
glucose control, tobacco cessation, and antiplatelet
therapy.
The most effective approach to decreasing cardiovas-
cular mortality is to address hypertension first, then
hyperlipidemia, and finally glucose control [5]. Recom-
mended treatment goals for these risk factors are listed
in table 1[6]. The independent role of intensive glucose
control in the reduction of macrovascular disease has
never been proven in a large prospective randomized
controlled trial. The goals for A1c were established
based on evidence linking a reduction in microvascular,
not macrovascular, outcomes to A1c values of < 7%
[7-9].
Summary Approach to Specific Vascular Beds:
Cardiovascular disease
The ADA recommends cardiovascular screening in
select patients with diabetes despite the lack of evidence
for improved outcomes. Screening is recommended in
patients with typical or atypical angina, abnormal EKG
suggestive of ischemia or infarct, and age > 35 years
with sedentary lifestyle and planning to start a vigorous
exercise program. This recommendation is based upon
expert opinion.
The San Antonio Heart Study demonstrated that the
risk for a cardiovascular event was similar in patients
with diabetes and no history of CVD as in patients with-
out diabetes and a history of CVD [10]. As a result,
many organizations have designated diabetes as a cardi-
ovascular risk equivalent. Despite this increased risk
there has been no evidence that screening for disease in
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This is believed to be due to the type of atherosclerotic
lesion that patients with diabetes have. Most ischemic
events originate from an atherosclerotic plaque that is
not obstructive and therefore would not be detected by
testing. These events are believed to be due to endothe-
lial dysfunction and decreased nitric oxide production,
leading to a state of hyper-constriction as well as an
increase in unstable plaque and plaque rupture [11].
Silent ischemia is more common in patients with dia-
betes and there are no symptoms suggestive of an event.
Studies have suggested that silent ischemia is present in
up to 20-50% of patients with diabetes [12]. The DIAD
study looked at over 1,000 patients with type 2 diabetes
without a history of CAD and without any cardiac
symptoms. The aim of the study was to look for predic-
tors of silent ischemia in people with type 2 diabetes.
T h ei n i t i a lr e s u l t so ft h i ss t u d yf o u n dt h a t2 2 %o f
patients had silent ischemia, and the strongest predic-
tors for abnormality were cardiac autonomic neuropa-
thy, male sex, and diabetes duration. The so called
traditional risk factors weren o tn o t e dt ob ep r e d i c t o r s
[13]. The five year follow up data is not yet available.
If screening is necessary, the test of choice is the exer-
cise stress test. A plain stress test without imaging may
be appropriate for male patients with a normal EKG,
good exercise tolerability, and asymptomatic patients
without a history of a cardiovascular event. There is less
validity in this test when women and higher risk patients
are being evaluated. The addition of imaging with single
photon emission computed tomography (SPECT)
increases the sensitivity and specificity of this screening
tool. The sensitivity and specificity of the SPECT imaging
stress test is about 88% and 75% respectively [14]. Other
powerful predictors of prognosis can be attained from
the stress test in addition to EKG changes and perfusion
defects. These include a poor exercise capacity, exercise
induced angina, low or a fall in peak blood pressure,
reduced heart rate recovery at 1-2 minutes post exercise,
and ventricular arrhythmias [14].
Screening for subclinical atherosclerosis has been sug-
gested as a possible tool to assess cardiovascular risk.
This includes coronary artery calcium (CAC) and caro-
tid intima media thickness (CIMT). A low CAC or
CIMT is very predictive of a low risk for a cardiovascu-
lar event. However, studies have reported evidence of
subclinical atherosclerosis in 60-70% of patients with
diabetes [14]. These scores are a measure of athero-
sclerotic burden but do not measure the severity or vul-
nerability of plaque. Therefore, the utility of these tests
in changing prognosis or therapy is minimal but may be
of some usefulness in certain patients with intermediate
risk.
The guidelines for therapy in patients with a previous
cardiovascular event are straightforward. A beta blocker,
angiotensin-converting enzyme inhibtor (ACE) or angio-
tensin receptor blocker (ARB), statin therapy, and antic-
oagulation with either aspirin or clopidogrel are
recommended [15]. However, treatment for asympto-
matic cardiovascular disease is controversial. There have
been multiple studies questioning the most effective
approach for patients with stable and unstable CAD.
Table 2 gives a brief summary of outcome data for
some of the major studies.
The Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) trial enrolled
over 2,000 patients with asymptomatic angiographical
evidence of CAD [16]. No statistical difference in the
primary outcome (death from any cause and nonfatal
MI) or the secondary outcome (death, stroke, MI) was
noted between percutaneous coronary intervention
(PCI) with optimal medical therapy (MT) versus MT
a l o n e( p=0 . 6 2 ) .T h e r ew a sas l i g h ti m p r o v e m e n ti n
angina free status in the PCI plus MT group (74%) ver-
sus the MT only group (72%) (p = 0.35). One limitation
to this study is that drug-eluting stents were not avail-
able for use at the time of the study, and as a result
bare metal stents were almost exclusively used. This
trial suggests that MT may be just as effective as PCI in
prevention of death and nonfatal MI in patients with
stable CAD.
The Bypass Angioplasty Revascularization Investiga-
tion (BARI) trial evaluated the effectiveness of PCI ver-
sus coronary artery bypass grafting (CABG) in over
1,800 patients with symptomatic multivessel CAD [17].




Blood pressure (ADA) < 130/80 mmHg
LDL-C (ADA) < 100 mg/dl (very high risk)
< 70 mg/dl (highest risk)
HDL-C (ADA) > 40 mg/dl (men)
> 50 mg/dl (women)
Triglyceride (ADA) < 150 mg/dl
Table 2 Outcome data from the COURAGE, BARI, and
BARI 2D Trials [16-18]
Trial Outcome PCI CABG MT
COURAGE Death from any cause/nonfatal MI* 19% 18.5%
Angina free status 74% 72%
BARI Survival* 71% 73.5%
Survival (Diabetes subgroup) 45.5% 57.8%
BARI 2D Survival* 88.3% 87.8%
* Not statistically significant
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groups. In a sub group of patients with diabetes and
multivessel disease, CABG conferred higher survival
rates (57.8%) in comparison to PCI (45.5%) (p = 0.025).
This suggests that patients with diabetes and diffuse
CAD may have better survival outcomes with CABG.
The Bypass Angioplasty Revascularization Investiga-
tion in Type 2 Diabetes (BARI 2D) trial examined over
2,000 patients with type 2 diabetes and angiographical
evidence of CAD [18]. There was no difference in the
primary outcome of survival between the intervention
group (PCI or CABG) versus the MT group (p = 0.97).
There was also no difference when prompt revasculari-
zation was utilized. There was a statistically significant
decrease in cardiovascular events with prompt CABG
(22.4%) versus MT (30.5%) (p = 0.01). This was mainly
due to the decrease in nonfatal MI with CABG (7.4%)
versus MT (14.6%). This trial also looked at the use of
insulin sensitizing agents versus insulin provisional ther-
apy with a goal A1c of 7.0%. No statistical significance
was seen in the primary outcome between the two dif-
ferent therapies (p = 0.89). A similar A1c goal of 7.0%
in the insulin sensitization and 7.5% in the insulin provi-
sion group was obtained [18].
Take Home Points
1. Diabetes is considered a cardiovascular risk
equivalent.
2. Subclinical atherosclerosis is present in up to 60-
70% of patients with type 2 diabetes.
3. PCI is no more effective than optimal medical
therapy in patients with type 2 diabetes and asymp-
tomatic atherosclerosis.
4. Patients with type 2 diabetes and diffuse athero-
sclerosis may benefit more from CABG than PCI.
Summary: Approach to Specific Vascular Beds:
Peripheral vascular disease
Peripheral arterial disease (PAD) affects 20-30% of
patients with diabetes mellitus and is associated with
increased coronary heart disease, stroke, and all cause
mortality [19]. Risk factors for PAD in patients with dia-
betes include increasing age, smoking, hypertension,
dyslipidemia, neuropathy, and elevated CRP. Typically
this involves the femoral-popliteal and tibal vessels and
is a more diffuse disease. Over 50% of these patients
have asymptomatic disease due to the distal location
and associated neuropathy that is usually present. Most
will have atypical symptoms which manifest as leg fati-
gue and slower gait. They may experience intermittent
vascular claudication which must be distinguished from
neurogenic claudication. Vascular claudication may
manifest as pain, cramping, or aching in the legs that is
reproducible with walking exercise and goes away with
standing and rest. This is different than neurogenic
claudication in that the patient needs to sit down for
the symptoms to resolve. Patients who get this vascular
claudication at rest may develop nonhealing ulcers, or
gangrene, which is considered critical limb ischemia and
is a medical emergency [20].
Due to the vague nature of the symptomatology and
the severe burden that PAD places on patients with dia-
betes, the ADA has recommended a screening ankle
brachial index (ABI) in all patients over 50 years of age
[6]. This should be repeated every 5 years and should be
considered in patients < 50 yrs of age who have other
risk factors [20]. The ABI is a diagnostic screening tool
where the ratio of systolic blood pressure in the ankle is
divided by the systolic blood pressure in the arm (figure
1). This test has a sensitivity of 95% and a specificity of
almost 100% [20,21]. A false elevation in ABI may occur
due to medial arterial calcification making the arteries
poorly compressible. This is usually considered when
the ABI is > 1.30 or if PAD is still suspected in a patient
with a normal ABI value (table 3).
A pulse volume recording (PVR) is the next test uti-
lized to find the location and severity of the lesion. An
exercise treadmill test may be useful to induce the
patient’s symptoms and to determine pre and post exer-
cise ABI values. These patients will usually have a > 20
mmHg drop in ankle pressure after exercise [20].
Duplex ultrasound, magnetic resonance angiogram
(MRA), and xray angiography are then utilized for
patients in whom a revascularization procedure is
intended.
Therapy for these patients consists of modification of
risk factors, a supervised exercise program, pharma-
cotherapy, and revascularization procedures. Smoking is
the most important modifiable risk factor for the pro-
gression of PAD [19]. Patients with diabetes have a risk
of developing PAD that is four times the general popu-
lation and patients that smoke and have diabetes have
an additional 2.5 fold increased risk [22]. Poor wound
healing, increased risk of amputation, and increased
mortality has been attributed to smoking. However,
smoking cessation has been associated with a 10 year
survival rate of 82% versus 46% for patients that con-
tinue to smoke [23]. There is no good evidence that
treatment of glycemia, hypertension, or hyperlipidemia
improves limb outcomes in patients with diabetes and
PAD. This is due to lack of studies evaluating the com-
bination of patients with diabetes and PAD. However,
based on extrapolation from cardiovascular studies, it is
believed that intensive therapy of these conditions will
improve outcomes in these patients.
Antiplatelet therapy with aspirin is recommended for all
patients with diabetes who have a 10 year estimated cardi-
ovascular risk > 10%, unless there are contraindications to
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60 years of age who have at least one additional risk factor
(family history CVD, hypertension, smoking, dyslipidemia,
or albuminuria) [6]. In a sub-analysis of the Clopidogrel
versus aspirin in Patients at Risk of Ischemic Events
(CAPRIE) trial, clopidogrel in patients with PAD was
associated with a 24% risk reduction in vascular events
(MI, ischemic stroke, and vascular death) in comparison
with aspirin [24]. Despite these results, aspirin is still
recommended as first line therapy.
Only 1-2% of patients with peripheral vascular disease
will go on to develop critical limb ischemia. The major-
ity of patients will continue with chronic stable claudica-
tion. Therefore, most treatment is aimed at improving
claudication symptoms and walking distance. Supervised
exercise therapy of at least three times a week for three
months is associated with improved outcomes and has
been shown to be as effective as revascularization ther-
apy [25]. Cilostazol, a phosphodiesterase type III inhibi-
tor, may be useful in symptomatic PAD and is
associated with increased maximal walking time,
Figure 1 Ankle brachial index (ABI). Blood pressure cuffs are placed on both arms and ankles. Systolic blood pressures are measured at the
brachial artery and dorsalis pedis artery with the assistance of an ultrasound Doppler. Two measurements are taken from each arm and leg and
then recorded as an average. The ABI is then calculated when the systolic blood pressure in the ankle is divided by the systolic blood pressure
in the arm (21).
Table 3 ABI values that correspond to severity of PAD
[20,23]
ABI Typical symptoms
Normal 0.91-1.30 Asymptomatic claudication
Mild 0.70-0.90 Intermittent claudication
Moderate 0.40-0.69 Daily rest pain
Severe < 0.40 Focal tissue necrosis
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[19]. Its use is contraindicated in patients with heart
failure. Revascularization procedures are indicated in
patients that fail conservative therapy, have non-healing
ulcerations, gangrene, or critical limb ischemia.
Percutaneous transluminal angioplasty (PTA), with or
without stent placement, is best suited for short segment
stenosis or large bore vessels while surgical revasculari-
zation is better suited for multivessel disease involving
smaller and more distant vessels. Guidelines from the
American College of Cardiology and the American
Heart Association (ACC/AHA) recommend PTA as pri-
mary therapy for common and/or external iliac artery
stenosis and occlusions with stenting as the primary
therapy for those lesions. Stent placement is not recom-
mended in the femoral, popliteal, or tibial arteries due
to the high rate of restenosis [26].
Take Home Points
1. ADA recommends a screening ABI every 5 years
in patients with diabetes over the age of 50.
2. Smoking is the most important modifiable risk
factor for the progression of PAD.
3. Revascularization procedures are indicated in
patients that fail conservative therapy, have non-
healing ulcerations, gangrene, or critical limb
ischemia.
Summary: Approach to Specific Vascular Beds:
Cerebrovascular disease
Despite no direct relationship between hyperglycemia
and stroke incidence, patients with diabetes have a two
to four fold increased risk of stroke over the general
population [1]. Insulin resistance and the inflammatory
cascade have been correlated with an increased stroke
incidence [27]. Hyperglycemia has been linked to recur-
r e n c eo fs t r o k ei np a t i e n t sw i t hd i a b e t e st h a ti s2t o5
times that of patients without diabetes. There is also an
increased risk of morbidity and mortality with a 5 year
survival rate of only 20% [28]. Ischemia causes the
majority of strokes, which are mainly due to occlusion
of the small paramedial penetrating arteries that lead to
small white matter infarcts, lacunar infarcts. This has
also been associated with an increase in stroke related
dementia [28].
Risk factors for stroke in patients with diabetes
include hypertension, hyperglycemia, hyperlipidemia,
tobacco use, metabolic syndrome, hyperuricemia, protei-
nuria, atrial fibrillation, and other vascular diseases.
Hypertension is the single most important risk factor.
This risk can be decreased with antihypertensive agents
by 30-40%. ACE inhibitors and ARB medications have
been shown to be superior to other antihypertensive
medications in the prevention of stroke [29-31]. Calcium
channel blockers have also shown significant benefit in
patients with diabetes [27]. In the Syst-Eur trial, over
4,000 patients > 60 years of age with hypertension were
randomized to either nitrendipine plus enalapril and
hydrochlorothiazide if needed or placebo. The primary
endpoint, composite of fatal and nonfatal stroke, was
met with a 42% reduction in the therapeutic arm. This
study suggests that the calcium channel blocker, nitren-
dipine, has an even greater benefit in patients with dia-
betes. Overall mortality was decreased by 55% in the
diabetic population versus 6% in the nondiabetic popu-
lation [27].
Hyperlipidemia is also important risk factor in the
prevention of stroke and statin therapy has been shown
to reduce this risk. Studies with statin interventions
have shown a 20-50% reduction in stroke [32,33]. Treat-
ment of hyperglycemia in the prevention of stroke is
controversial but there was a trend for reduction in
stroke risk in the UKPDS. Risk of stroke decreased by
17% with every 1% decrease in A1c [7]. Insulin sensiti-
zers have shown some benefit in the risk of stroke in
patients with diabetes. Patients in the UKPDS metfor-
min subgroup found a 42% reduction in stroke risk [8].
Therapy with both of the commercially available PPAR
agonists (TZD) have shown improved cerebral hemody-
namics and decreased oxidative stress. They are believed
to work centrally on the neural and microglial cells,
affecting the post stroke prognosis. In the PROactive
study, Pioglitazone was associated with a decrease in
recurrent stroke by 47% [34].
Intensive glucose therapy in patients with or without
diabetes is very important during the acute phase of an
ischemic stroke in order to limit the ischemic area.
Acute stress hyperglycemia occurs with about 2/3 of
ischemic strokes. This provokes anaerobic metabolism,
lactic acidosis, and free radical formation, which in turn,
leads to lipid peroxidation and cell lysis in the metaboli-
cally challenged tissue. There is an area in an acute
stroke called the pneumbra. This area has not yet
infarcted but is at risk. In patients with hyperglycemia,
the infarct extends further into the penumbra leading to
an increased area of infarction and a worsening of dis-
ability [35]. Imaging studies have shown initial infarct
size and progression in hyperglycemic patients [27]. In
one study, normalization of glucose was associated with
a reduction in mortality by 4.6 times [36].
Interventional therapy has been associated with
increased risk in patients with diabetes. Thrombolytics
utilized in ischemic stroke are associated with a greater
risk of subsequent hemorrhage and patients have less
improvement in function than the general population.
Atherosclerotic plaque is also more prone to rupture in
diabetic patients. This is assumed to be the reason for
increased morbidity and mortality with recanalising
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into account when utilizing these therapies and deter-
mining the risk benefit ratio for patients with diabetes.
Take Home Points
1. Patients with diabetes have a 5 year survival rate
of only 20% after suffering a stroke.
2. Intensive glucose control is associated with a
reduction in area of cerebral infarction.
3. Interventional therapy is associated with increased
risk in patients with diabetes.
Summary
As the prevalence of diabetes continues to grow, the
prevalence of macrovascular complications will also
increase exponentially. There is no evidence that inten-
sive glucose control decreases the risk of these compli-
cations. However, multifactorial risk reduction
significantly decreases the risk for both primary and sec-
ondary prevention.
Silent ischemia in the cardiovascular, peripheral vascu-
lar, and cerebrovascular systems are very common in
patients with diabetes. Presentation and response to
therapy may be different for patients with diabetes com-
pared to their non-diabetic counterparts. Therefore,
physicians caring for these patients must have a high
index of suspicion and be up to date on the latest evi-
dence for prevention and therapy.
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